17β-estradiol upregulates striatin protein levels via Akt pathway in human umbilical vein endothelial cells

Shuhui Zheng¹, Peng Sun², Haimei Liu³, Runmei Li⁴, Lingli Long¹, Yuxia Xu¹, Suiqing Chen³, Jinwen Xu³*

¹ Research Center of Translational Medicine, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China, ² Department of Pathology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, ³ Department of Physiology, Basic Medical College, Guangzhou University of Chinese Medicine, University Town, Guangzhou, China, ⁴ School of Chinese Pharmaceutical Science, Guangzhou University of Chinese Medicine, University Town, Guangzhou, China

* xujinwen@gzucm.edu.cn

Abstract

17β-estradiol (E2) has been shown to have beneficial effects on the cardiovascular system. We previously demonstrated that E2 increases striatin levels and inhibits migration in vascular smooth muscle cells. The objective of the present study was to investigate the effects of E2 on the regulation of striatin expression in human umbilical vein endothelial cells (HUVECs). We demonstrated that E2 increased striatin protein expression in a dose- and time-dependent manner in HUVECs. Pretreatment with ICI 182780 or the phosphatidylinositol-3 kinase inhibitor, wortmannin, abolished E2-mediated upregulation of striatin protein expression. Treatment with E2 resulted in Akt phosphorylation in a time-dependent manner. Moreover, silencing striatin significantly inhibited HUVEC migration, while striatin overexpression significantly promoted HUVEC migration. Finally, E2 enhanced HUVEC migration, which was inhibited by silencing striatin. In conclusion, our results demonstrated that E2-mediated upregulation of striatin promotes cell migration in HUVECs.

Introduction

The striatin family of multidomain proteins has three members: striatin, SG2NA (striatin 3), and zinedin (striatin 4) [1–2]. These proteins contain multiple protein-binding domains: a caveolin-binding domain, a coiled-coil domain, a Ca2+-calmodulin-binding domain, and a WD-repeat domain [3]. They are involved in Ca2+-dependent pathways by binding calmodulin in the presence of Ca2+ ions, and interact with caveolin [4]. Striatin, a cytoplasmic protein, was identified in brain tissue, and is detectable in liver, skeletal muscle, the heart, and vascular cells [4–9]. A previous study demonstrated that a polymorphic variant in the striatin gene is associated with salt-sensitive blood pressure (BP) in people with hypertension. Striatin heterozygous knockout mice also demonstrate salt sensitivity of BP [10]. Furthermore, striatin
deficiency was found to increase vasoconstriction and decrease vascular relaxation [11]. These results suggest that striatin might regulate vascular function.

Estrogen has been shown to regulate cardiovascular function though genomic and nongenomic mechanisms [12–13]. The genomic effects of estrogen are mediated by nuclear estrogen receptors (ERs) that act as ligand-activated transcription factors. The nongenomic effects of estrogen are also mediated by ERs, although they occur relatively quickly and do not involve alterations in gene expression. In vascular endothelial cells, the nongenomic effects of estrogen were found to be associated with striatin [14]. Moreover, we previously showed that estrogen upregulates the expression of striatin, and inhibits cell migration in vascular smooth muscle cells [9]. The objective of the present study was to investigate the effects of estrogen on striatin expression in human umbilical vein endothelial cells (HUVECs).

**Methods**

**Reagents**

17β-Estradiol (E2), PD98059, and wortmannin were from Sigma-Aldrich (St. Louis, MO). ICI 182780 was from Tocris Cookson (Bristol, UK). Dulbecco’s modified Eagle’s medium (DMEM), Opti-MEM, and fetal bovine serum (FBS) were from Invitrogen (Carlsbad, CA). All other chemicals were of analytical grade and from Guangzhou Chemical Reagents (Guangzhou, China).

**Cell culture**

Human umbilical vein endothelial cells were cultured as previously described [15]. Cells were grown in a 5% CO2 atmosphere at 37˚C in DMEM without phenol, supplemented with penicillin and streptomycin, and 10% charcoal-stripped FBS (steroid free and delipidated, fetal bovine serum) (Biowest, S181F-500, Nuaille, France). Before experiments, cells were maintained in phenol red-free DMEM containing 1% FBS for 48 h. Chemical inhibitors were added to cells 30 min before starting other treatments.

**Immunoblotting**

Immunoblotting was performed as previously described [9]. Briefly, HUVECs in culture dishes maintained on ice were rinsed once with ice-cold phosphate-buffered saline before the addition of lysis buffer (100 mM Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol, 1 mM sodium orthovanadate, 1 mM NaF, and 1 mM phenylmethylsulfonyl fluoride). Cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The antibodies used were: striatin (BD Transduction Laboratories), Akt, and Ser 473 phosphorylated Akt (Cell Signaling Technology). Membranes were incubated with primary and secondary antibodies using standard techniques. Immunodetection was performed using enhanced chemiluminescence.

**Immunofluorescence**

HUVECs were grown on coverslips and treated accordingly. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X. Blocking was performed with 3% normal serum for 20 min. Cells were incubated with an antibody against striatin (BD Transduction Laboratories) and a FITC-conjugated secondary antibody (K00018968, Dako North America Inc., Dako, Denmark). After washing, the nuclei were counterstained with 4’-6-diamidino-2-phenylindole (Sigma). Immunofluorescence was visualized using an Olympus BX41 microscope (Tokyo, Japan) and recorded with a high-resolution DP70 Olympus digital camera.
Transfection experiments

Transfection experiments were performed as previously described [9]. Striatin siRNAs, including siRNA1 (SASI_Rn01_00107865), siRNA2 (SASI_Rn02_00266690), and siRNA3 (SASI_Rn01_00107867) were purchased from Origene. They were transfected into HUVECs using lipofectamine according to the manufacturer’s protocol. Cells (40% confluent) were serum-starved for 1 h, followed by incubation with 100 nM target siRNA or control siRNA for 6 h in serum-free media. Media supplemented with serum (10% final concentration) was then added for 42 h before experiments and/or functional assays were performed. Target protein silencing was assessed through immunoblotting up to 48 h after transfection.

For striatin overexpression assays, each plasmid (15 mg) was transfected into HUVECs using the Lipofectamine (Invitrogen) according to the manufacturer’s instructions. The transfected plasmids were as follows: overexpressed striatin plasmid and empty pcDNA3.1+ plasmid. These constructs were obtained from Genechem Co.Ltd. (Shanghai, China). All the inserts were cloned in pcDNA3.1+. As control, parallel cells were transfected with empty pcDNA3.1+ plasmid encoding a enhanced green fluorescent protein (EGFP). And the transfection efficiency was quantified by counting the percentage of cells that EGFP-positive using a microscope. Cells (60–70% confluent) were treated 24 h after transfection, and cellular extracts were prepared according to the experiments to be performed.

Cell migration and transwell assays

Cell migration was assayed as previously described [16–17]. Briefly, after transfection with siRNA, HUVECs were synchronized by replacing media with serum-free DMEM for 24 h. To create wounds, cell monolayers in culture dishes were scratched with 200-μl pipet tips. Cells were washed, and DMEM medium containing gelatin (1mg/mL) and cytosine b-D-arabinofuranoside hydrochloride (Ara-C, Sigma) (10mM), a selective inhibitor of DNA synthesis which does not inhibit RNA synthesis, was added. Migration was monitored for 24 h. Cells were imaged digitally with phase-contrast microscopy, and migration was quantified as the extent of gap closure using NIH Image J software (Bethesda, MD).

Transwell experiments were performed as previously described [18]. After transfection with the different siRNAs, cells were seeded in the upper chamber of transwell chambers (Corning Life Sciences, Lowell, MA, USA) and Ara-C (10 μM) was added. After 24 h, cells that invaded the lower surface of the membranes were fixed with methanol for 10 min, and stained with hematoxylin. The cells on the lower side of the membrane were counted and averaged in six high-power fields with a light microscope.

Statistical analysis

Data are presented as mean ± standard deviation, and represent at least three independent experiments. Statistical comparisons were made using the Student’s t-test or one-way analysis of variance followed by a post hoc analysis (Tukey test) where applicable to identify significant differences in mean values. p<0.05 was considered statistically significant.

Results

E2 increases striatin protein expression in HUVECs

Immunoblotting showed that E2 (0.1nM–1.0μM) upregulated striatin expression with the maximal effect achieved using 10 nM E2 (Fig 1A). Furthermore, E2 (10 nM) increased striatin
expression in a time-dependent manner within 48 h (Fig 1B). Immunofluorescence consistently demonstrated that treatment with 10 nM E2 for 24 h increased cytoplasmic striatin protein expression in HUVECs (Fig 1C).
E2 increases striatin protein expression via the Akt pathway

To determine the signaling pathways involved in E2-induced upregulation of striatin expression, HUVECs were pretreated with the mitogen-activated protein kinase inhibitor, PD98059, the phosphatidylinositol-3 kinase inhibitor, wortmannin, and the Src inhibitor, PP2. We found that wortmannin inhibited E2-induced striatin protein expression (Fig 2A). We furthermore found this inhibitory effect of wortmannin was in a dose manner (Fig 2B). Treatment with E2 resulted in Akt phosphorylation (Ser 473) from 5 min to 30 min (Fig 2C).

Silencing striatin in HUVECs inhibits cell migration

When transfected with striatin siRNAs, striatin expression was significantly reduced (Fig 3A). Silencing striatin increased HUVEC gap distance by approximately 180% (Fig 3B). Consistently, transwell experiments showed that silencing striatin significantly reduced the number of cells that invaded the lower surface of the membranes by 60% (Fig 3C).

Striatin overexpression in HUVECs promotes cell migration

When transfected with plasmid striatin, striatin expression was significantly increased (Fig 4A). Striatin overexpression decreased HUVEC gap distance (Fig 4B). Consistently, transwell experiments showed that striatin overexpression significantly increased the number of cells that invaded the lower surface of the membranes by approximately 100% (Fig 4C).

E2 promotes HUVEC migration via striatin

Next, we explored the effects of striatin on E2-induced cell migration in HUVECs. E2 significantly decreased HUVEC gap distance by 50% (Fig 5), and increased the number of cells that migrated to the membrane by 90% (Fig 6). These results indicated that E2 increases HUVECs migration. However, after transfected with siRNAs, E2-induced cell migration distance and the number of migrated cells were significantly reduced (Figs 5 and 6).

Discussion

The striatin scaffold proteins interact with signaling proteins, including members of the germinal center kinase family (MST3, MST4, and YSK1), NCK-interacting kinase (NIK), and TRAF2- and NCK-interacting kinase (TNIK) [19]. The protein complex, striatin interacting phosphatase and kinase (STRIPAK), acts as a signaling hub that regulates multiple cellular functions [2]. Although the nongenomic effects of E2 on vascular endothelial cells have been shown to be regulated by striatin [14], little is known about the effects of E2 on striatin expression in endothelial cells. Furthermore, a previous study showed that incubation of EA.hy926 endothelial cells with aldosterone increases striatin protein and mRNA expression [20]. We previously demonstrated that E2 increases striatin protein levels in vascular smooth muscle cells (VSMCs) [9]. Therefore, we hypothesized that E2 regulates striatin expression in HUVECs. We found that E2 (0.1 nM–1.0 μM) significantly upregulated striatin expression in HUVECs (Fig 1). Immunofluorescence further confirmed that cytoplasmic striatin expression was increased in response to treatment with E2 (Fig 1).

To determine the signaling pathways involved in E2-induced upregulation of striatin, we treated HUVECs with several signal transduction inhibitors. We previously showed that ERK1/2 is involved in E2-induced upregulation of striatin in VSMCs [9]. However, in the present study, we found that wortmannin suppressed E2-induced upregulation of striatin expression in HUVECs, while PP2 and PD98059 had no effects (Fig 2). Previously found that estrogen induced rapid activation of Akt in EA.hy926 endothelial cells [21]. Herein, we
consistently found that treatment with 10 nM E2 resulted in Akt phosphorylation within 5 min (Fig 2). These results indicated that E2 upregulates striatin via the Akt pathway in HUVECs. Interestingly, striatin was found to play a role in the estrogen-induced rapid
activation of Akt in EA.hy926 endothelial cells [14]. These observations suggest striatin may be involved in crosstalk between the genomic and nongenomic effects of E2 in HUVECs.

Cardiovascular disease is less frequent in premenopausal women compared with men, but increases rapidly in postmenopausal women [22]. Although the primary results from the Women’s Health Initiative showed no cardiovascular benefit from estrogen replacement therapy [23], the Danish Osteoporosis Prevention Study showed that women who received hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction [24]. This beneficial effect of E2 on the cardiovascular

Fig 3. Silencing striatin in HUVECs inhibits cell migration. (A) HUVECs were transfected with scrambled siRNA or striatin targeted siRNA 1, 2 or 3 for 48h. Striatin densitometry values were adjusted to actin intensity, then normalized to expression from the control sample. Expression in CON group was normalized to 1, \( p < 0.01 \) versus CON. Bars represent SD, n = 4. (B) After transfection assays, HUVECs were scrapped to create a cell-free (wounded) area. Cells were incubated with 10nM E2 or with solvent as control for another 24h. Migration was monitored. Representative images of cell migration are shown. Gap distance in CON group was normalized to 1, \( p < 0.01 \) versus CON. Bars represent SD, n = 6. (C) After transfected with striatin siRNA1, 2, 3 or scrambled siRNA for 24h, transwell experiments were performed. Representative images of transwell experiments are shown. The number of the invaded cell in the lower surface of the membrane in CON group was normalized to 1, \( p < 0.01 \) versus CON. Bars represent SD, n = 6.

https://doi.org/10.1371/journal.pone.0202500.g003
Fig 4. Striatin overexpression in HUVECs promotes cell migration. (A) HUVECs were transfected with control plasmids (PL-con) or striatin targeted plasmids (PL-striatin). Striatin densitometry values were adjusted to actin intensity, then normalized to expression from the control sample. Expression in PL-con group was normalized to 1. *p<0.01 versus CON. Bars represent SD, n = 4. (B) After transfection assays, HUVECs were scrapped to create a cell-free (wounded) area. Migration was monitored. Representative images of cell migration are shown. Gap distance in PL-con group was normalized to 1. *p<0.01 versus CON. Bars represent SD, n = 6. (C) After transfected with striatin plasmids, transwell experiments were performed. Representative
system was shown to be associated with accelerated vascular endothelial repair through the promotion of endothelial migration [25–26]. In cell culture, E2 has been shown to promote the growth and migration of vascular endothelial cells, an essential component of vascular healing [27–28]. It was found that silencing striatin 4 suppresses cell migration in several cancer cell lines [29]. We assumed that E2-induced up-regulation of striatin might affect cell migration in HUVECs. We furthermore found that striatin overexpression significantly increased cell migration in HUVECs, while, striatin silencing reduced cell migration. However, previous study demonstrated that E2 in vitro directly promoted HUVECs migration [30]. Our results indicated E2-induced cell migration in HUVECs might partially through up-regulation of striatin expression. Finally, with cell migration and transwell assays, we demonstrated that silencing striatin in HUVECs significantly inhibited E2-induced cell migration.

Conclusions

In conclusion, our findings indicated that E2-induced cell migration may be associated with upregulation of striatin in HUVECs.

Fig 5. Wound scratch assay showed E2 promotes HUVEC migration via striatin. HUVECs were transfected with striatin siRNA1, 2, 3 or scrambled siRNA for 24h. Then cells were scrapped to create a cell-free (wounded) area. Cells were incubated with 10nM E2 or with solvent as control for another 24h. Migration was monitored. Representative images of cell migration are shown. Gap distance in CON group was normalized to 1, "p<0.01 versus CON. Bars represent SD, n = 6.

https://doi.org/10.1371/journal.pone.0202500.g005
Fig 6. Transwell assay showed E2 promotes HUVEC migration via striatin. After transfected with striatin siRNA1, 2, 3 or scrambled siRNA for 24h, transwell experiments were performed. Representative images of transwell experiments are shown. The number of the invaded cell in the lower surface of the membrane in CON group was normalized to 1, *p<0.01 versus CON. Bars represent SD, n = 6.

https://doi.org/10.1371/journal.pone.0202500.g006

Supporting information
S1 Data. All relevant raw data are within RAW DATA.pptx files.
(PPTX)

Acknowledgments
We thank Richard Robins, PhD, from Liwen Bianji, Edanz Editing China, for editing the English text of a draft of this manuscript.

Author Contributions
Data curation: Haimei Liu.
Formal analysis: Runmei Li, Jinwen Xu.
Investigation: Shuhui Zheng, Jinwen Xu.
Methodology: Shuhui Zheng, Peng Sun.
Project administration: Shuhui Zheng, Jinwen Xu.
Resources: Lingli Long.
Software: Yuxia Xu, Suiqing Chen.
Writing – original draft: Jinwen Xu.

References
1. Benoist M, Gaillard S, Castets F. The striatin family: a new signaling platform in dendritic spines. J Physiol Paris. 2006 Mar-May; 99(2–3):146–53. https://doi.org/10.1016/j.jphysparis.2005.12.006 PMID: 16460920

2. Hwang J, Pallas DC. STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem Cell Biol. 2014 Feb; 47:118–48. https://doi.org/10.1016/j.biocel.2013.11.021 PMID: 24339164
3. Castets F, Bartoli M, Barnier JV, Baillat G, Salin P, Moqrich A, et al. A novel calmodulin-binding protein, belonging to the WD-repeat family, is localized in dendrites of a subset of CNS neurons. J Cell Biol. 1996 Aug; 134(4):1051–62. PMID: 8769426

4. Castets F, Rakitina T, Gaillard S, Moqrich A, Mattei MG, Monneron A, Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J Biol Chem. 2000 Jun 30; 275(26):19970–7. https://doi.org/10.1074/jbc.M909782199 PMID: 10748158

5. Moqrich A, Mattei MG, Bartoli M, Rakitina T, Baillat G, Monneron A, et al. Cloning of human striatin cDNA (STRN), gene mapping to 2p22-p21, and preferential expression in brain. Genomics. 1998 Jul 1; 51(1):136–9. https://doi.org/10.1006/geno.1998.5342 PMID: 9693043

6. Nader M, Alostabi S, Alsolmali R, et al. Cardiac striatin interacts with caveolin-3 and calmodulin in a calcium sensitive manner and regulates cardiomyocyte spontaneous contraction rate. Can J Physiol Pharmacol. 2017 Aug 19.

7. Moreno CS, Park S, Nelson K, Ashby D, Hubalek F, Lane WS, et al. WD40 repeat proteins striatin and S/G(2) nuclear autoantigens are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. J Biol Chem. 2000 Feb 25; 275(8):5257–63. PMID: 10861496

8. Bernelot Moens SJ, Schnitzler GR, Nickerson M, Guo H, Ueda K, Lu Q, et al. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation. 2012 Oct 16; 126(16):1993–2004. https://doi.org/10.1161/CIRCULATIONAHA.112.124529 PMID: 22997253

9. Zheng S, Chen X, Hong S, Long L, Xu Y, Simoncini T, et al. 17β-Estradiol inhibits vascular smooth muscle cell migration via up-regulation of striatin protein. Gynecol Endocrinol. 2015; 31(8):618–24. https://doi.org/10.3109/09513590.2015.1021325 PMID: 26220767

10. Garza AE, Rairy CM, Sun B, Williams J, Lasky-Su J, Baudrard R, et al. Variants in striatin gene are associated with salt-sensitive blood pressure in mice and humans. Hypertension. 2015 Jan; 65(1):211–217. https://doi.org/10.1161/HYPERTENSIONAHA.114.04233 PMID: 25368024

11. Garza AE, Pojoga LH, Moize B, Hafiz WM, Opsasnick LA, Siddiqui WT, et al. Critical Role of Striatin in Blood Pressure and Vascular Responses to Dietary Sodium Intake. Hypertension. 2015 Sep; 66(3):674–80. https://doi.org/10.1161/HYPERTENSIONAHA.115.05600 PMID: 26169051

12. Simoncini T. Mechanisms of action of estrogen receptors in vascular cells: relevance for menopause and aging. Climacteric. 2009; 12 Suppl 1:6–11.

13. Fu XD, Simoncini T. Extra-nuclear signaling of estrogen receptors. IUBMB Life. 2008 Aug; 60(8):502–10. https://doi.org/10.1002/iub.80 PMID: 18618586

14. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A. 2004 Dec 7; 101(49):17126–31. https://doi.org/10.1073/pnas.0407492101 PMID: 15569929

15. Zheng S, Huang J, Zhou K, Xiang Q, Zhang Y, Tan Z, et al. Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. J Cell Mol Med. 2012 Feb; 16(2):296–305. https://doi.org/10.1111/j.1582-4934.2011.01305.x PMID: 21418517

16. Jiang P, Xu J, Zheng S, Huang J, Xiang Q, Fu X, et al. 17β-Estradiol down-regulates lipopolysaccharide-induced MCP-1 production and cell migration in vascular smooth muscle cells. J Mol Endocrinol. 2010 Aug; 45(2):87–97. https://doi.org/10.1677/JME-09-0166 PMID: 20538789

17. Zheng S, Huang J, Zhou K, Xiang Q, Zhang Y, Tan Z, et al. Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. J Cell Mol Med. 2012 Feb; 16(2):296–305. https://doi.org/10.1111/j.1582-4934.2011.01305.x PMID: 21418517

18. Zheng S, Huang J, Zhou K, Zhang C, Xiang Q, Tan Z, et al. 17β-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS One. 2011; 6(7): e22439. https://doi.org/10.1371/journal.pone.0022439 PMID: 21818323

19. Goudreau M, D’Ambrosio LM, Kean MJ, Mullin MJ, Larsen BG, Sanchez A, et al. A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics. 2009 Jan; 8(1):157–71. https://doi.org/10.1074/mcp.M800266-MCP200 PMID: 18782753

20. Pojoga LH, Coutinho P, Rivera A, Yao TM, Maldonado ER, Youte R, et al. Activation of the mineralocorticoid receptor increases striatin levels. Am J Hypertens. 2012 Feb; 25(2):243–9. https://doi.org/10.1038/ajh.2011.197 PMID: 22089104

21. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000 Oct 13; 87(8):677–82. PMID: 11029403

22. Kander MC, Cui Y, Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. J Cell Mol Med. 2017 May; 21(5):1024–1032. https://doi.org/10.1111/jcmm.13038 PMID: 27957792
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17; 288(3):321–33. PMID: 12117397

24. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9; 345:e6409. https://doi.org/10.1136/bmj.e6409 PMID: 23048011

25. Arnal JF, Fontaine C, Billon-Gales A, Favre J, Laurell H, Lenfant F, et al. Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol. 2010; 30:1506–1512. https://doi.org/10.1161/ATVBAHA.109.191221 PMID: 20631350

26. Razandi M, Pedram A, Levin ER. Estrogen signals to the preservation of endothelial cell form and function. J Biol Chem. 2000; 275:38540–38546. https://doi.org/10.1074/jbc.M007555200 PMID: 10988297

27. Geraldès P, Siros MG, Bernatchez PN, Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2002; 22:1585–1590. PMID: 12377734

28. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995; 91:755–763. PMID: 7530174

29. Wong M, Hyodo T, Asano E, Funasaka K, Miyahara R, Hirooka Y, et al. Silencing of STRN4 suppresses the malignant characteristics of cancer cells. Cancer Sci. 2014 Dec; 105(12):1526–32. https://doi.org/10.1111/cas.12541 PMID: 25250919

30. Li P, Wei J, Li X, Cheng Y, Chen W, Cui Y, et al. 17β-Estradiol Enhances Vascular Endothelial Ets-1/miR-126-3p Expression: The Possible Mechanism for Attenuation of Atherosclerosis. J Clin Endocrinol Metab. 2017 Feb 1; 102(2):594–603. https://doi.org/10.1210/jc.2016-2974 PMID: 27870857